Correspondence 0001493152-23-026472 from IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC.
Date: Aug. 2, 2023 · CIK: 0001834105 · Accession: 0001493152-23-026472
AI Filing Summary & Sentiment
File numbers found in text: 333-253037
Letter
Securities and Exchange Commission Division of Corporation Finance Attention: Timothy Buchmiller Registration Statement on Form S-1 File No. 333-253037
Re: Impact BioMedical Inc.
Dear Mr. Buchmiller:
Reference is made to the Registration Statement on Form S-1 (File No. 333-253037) (as amended to date, the “Registration Statement”) filed by Impact BioMedical Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “Commission”).
A record date of July 10, 2023 was set for the distribution of 485,161,488 shares of the Company’s common stock (the “Shares”), which is expected to occur at 5:00 p.m. eastern time on August 8, 2023. The Company hereby requests that the effectiveness of the Registration Statement be accelerated such that it be declared effective as of 4:30 p.m. Eastern time on August 4, 2023, or as soon thereafter as practicable.
If you have any questions or require any additional information regarding this request, please contact Darrin M. Ocasio of Sichenzia Ross Ference LLP at (212) 398-1493. We request that we be notified of the effectiveness of the Registration Statement by a telephone call to Mr. Darrin M. Ocasio and that such effectiveness also be confirmed in writing to the address above.
Very
truly yours,
Impact
BioMedical Inc.
Show Raw Text
CORRESP
1
filename1.htm
August
2, 2023
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street N.E.
Washington,
D.C. 20549
Attention:
Timothy
Buchmiller
Re:
Impact
BioMedical Inc.
Registration
Statement on Form S-1
File
No. 333-253037
Dear
Mr. Buchmiller:
Reference
is made to the Registration Statement on Form S-1 (File No. 333-253037) (as amended to date, the “Registration Statement”)
filed by Impact BioMedical Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “Commission”).
A
record date of July 10, 2023 was set for the distribution of 485,161,488 shares of the Company’s common stock (the “Shares”),
which is expected to occur at 5:00 p.m. eastern time on August 8, 2023. The Company hereby requests that the effectiveness of the Registration
Statement be accelerated such that it be declared effective as of 4:30 p.m. Eastern time on August 4, 2023, or as soon thereafter as
practicable.
If
you have any questions or require any additional information regarding this request, please contact Darrin M. Ocasio of Sichenzia Ross
Ference LLP at (212) 398-1493. We request that we be notified of the effectiveness of the Registration Statement by a telephone call
to Mr. Darrin M. Ocasio and that such effectiveness also be confirmed in writing to the address above.
Very
truly yours,
Impact
BioMedical Inc.
By:
/s/
Frank D. Heuszel
Frank
D. Heuszel
Chief
Executive Officer
Cc:
Frank
D. Heuszel
Darrin
M. Ocasio